About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Ultrasound to Drive Cancer Drug Therapies

by Anjali Aryamvally on March 24, 2018 at 1:17 PM
Ultrasound to Drive Cancer Drug Therapies

While ultrasound has been for decades to image organs, check blood flow, and monitor the development of fetuses, new study tests the use of these pulsed sound waves to direct and focus cancer drug therapies. The study is being conducted by a Norwegian biotech company called Phoenix Solutions AS in collaboration with the Translational Genomics Research Institute (TGen), a Phoenix, Arizona-based biomedical research facility.

In laboratory tests, TGen will help analyze the effectiveness of a technology called Acoustic Cluster Therapy (ACT), a unique approach to targeting cancer cells by concentrating the delivery of chemotherapies, making them more effective and potentially reducing their toxicity.

Advertisement


Humanscan Co. Ltd., a South Korean manufacture of ultrasound diagnostic imaging, is developing clinically applicable hardware optimized for ACT, which TGen will then validate.

Phoenix Solutions is using funding from Innovation Norway to conduct this research in advance of pancreatic cancer clinical trials planned later this year.
Advertisement

"We are very pleased to receive this grant, which will enable us to develop and validate an optimal ultrasound platform for clinical use of ACT. In their respective fields, Humanscan and TGen both represent the cutting edge of science, and we are confident this will contribute to the clinical success of our program," said Dr. Per Sontum, CEO of Phoenix Solutions.

TGen is a world leader in the development of novel therapeutics for the treatment of pancreatic cancer. The TGen team led the clinical development of one of the current standard-of-care regimens for this disease -- nab-paclitaxel plus gemcitabine. TGen currently is involved in 13 pancreatic cancer clinical programs.

"We are pleased that this research program has become a reality, and look forward to working with ACT. The concept represents a novel approach to targeted drug delivery and looks very promising," said Dr. Haiyong Han, a Professor in TGen's Molecular Medicine Division and head of the Basic Research Unit in TGen's Pancreatic Cancer Program.

Among the advantages of ultrasound technology: it is generally painless; non-invasive; does not require needles, injections or incisions; and patients are not exposed to ionizing radiation, making the procedure safer than diagnostic techniques such as X-rays and CT scans.

Humanscan CEO Sungmin Rhim said, "We are excited to enter into this collaboration with Phoenix (Solutions) and participate in the development of ACT. Ultrasound mediated, targeted drug delivery is an emerging therapy approach with great potential and we are delighted to be in the forefront of this development."

Phoenix Solutions also is considering this technology for use in addressing other types of cancer, including: liver, prostate and triple-negative breast cancer; and other diseases, including those involving inflammation and the central nervous system.



Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Research News

Cerebrospinal Fluid Leaks: Link to Traumatic Brain Injury and Dementia?
Cerebrospinal fluid (CSF) leaks are detected in approximately 1-3% of adults who have experienced a traumatic brain injury.
Astrocyte Activation Through Optogenetics: A New Hope in the Fight Against Alzheimer's
The optogenetic activation of hippocampal astrocytes can be viewed as a novel therapeutic avenue for addressing Alzheimer's disease.
Link Between Cholesterol and Inflammation in Alzheimer's Disease Identified
In Alzheimer's disease condition, the control and adjustment of ABCA7 levels in response to inflammation and the decrease in the availability of cholesterol.
Inflammatory Bowel Disease and Atopic Dermatitis Share Common Links
Atopic dermatitis (AD) and inflammatory bowel disease (IBD) can lead to alterations in the microbiome, and disruptions in the skin and gut barrier.
Vitiligo-Associated Autoimmunity Linked to Lower Health Risks
Gaining insights into mortality risks among vitiligo patients will enhance patient counseling, healthcare monitoring, and overall patient management strategies.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Ultrasound to Drive Cancer Drug Therapies Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests